StockData
Rein Therapeutics, Inc. logo

Rein Therapeutics, Inc. (RNTX) company profile

RNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.36−0.04 (-10.90%)

Close on Nov 17, 2026Market cap $30.75MP/E –Yield 0.00%

About Rein Therapeutics

Pharmaceutical Preparations, SIC 2834

The company is a clinical-stage biopharmaceutical business that develops novel therapeutics targeting orphan pulmonary and fibrosis indications with limited or no approved therapies. Its primary pipeline candidate is LTI-03, an inhaled peptide therapeutic derived from the Cav1 protein designed to protect lung epithelial cells and inhibit pro-fibrotic pathways in idiopathic pulmonary fibrosis. The company also developed LTI-01, a proenzyme for treating loculated pleural effusion, alongside preclinical programs for cystic fibrosis and systemic fibrosis, although active development on these secondary programs is paused. Because its drug candidates remain in clinical and preclinical development, the company has no commercialized products, generates no product sales revenue, and currently lacks commercial customers or internal sales, marketing, and distribution infrastructure.

The company operates without internal manufacturing facilities, relying entirely on third-party contract manufacturers for drug supplies. Its clinical development activities span multiple countries, including clinical trial sites located across the United States, the United Kingdom, Germany, Poland, Belgium, Australia, and New Zealand. The provided text does not state the company's headquarters location.

Summary of the business section of Rein Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Rein Therapeutics, Inc.
Headquarters
Austin, TX
Address
12407 N. Mopac Expy., Suite 250 #390 78758
Phone
(737) 802-1989
Website
reintx.com
Employees
10, Dec 31, 2025
Industry
Pharmaceutical Preparations
Fiscal year ends
December 31
Auditor
CBIZ CPAs P.C., New York, NY

Stock & identifiers

Ticker
RNTX
Former tickers
ALRN until Jan 10, 2025
Exchange
Nasdaq
IPO date
Jun 29, 2017
Shares outstanding
86M, Aug 12, 2026
Public float
$32.26M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-20 reverse, Nov 11, 2022
SEC CIK
1420565
CUSIP
00887A204
ISIN
US00887A2042
FIGI
BBG002454KR1
Share class FIGI
BBG002454KS0
EIN
13-4196017

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
James Brian WindsorSee Remarks, Director27,432
Rickenbach Josef H. VonDirector62,514
Alan A. MussoDirector–
Manuel AivadoDirector1,000
Reinhard J. AmbrosDirector2,549,982
William FaireyDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Brian Windsor
$882.70K$1.31M$0$-55–
FY2025
Timothy MCunningham
$433.94K$433.94K$0$-55–
FY2024
Brian Windsor
$1.76M$1.77M$475.96K$-3–
FY2024
Manuel CAlves Aivado
$1.33M$1.16M$475.96K$-3–
FY2024
Manuel CAlvesaivado
$1.33M$1.16M$475.96K$-3–
FY2023$0$0$417.90K$29–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOtherTotalvs. prior year
Brian Windsor, Ph.D.
President and Chief Executive Officer
$575.00K$287.50K$20.20K$882.70K-50%
Timothy M. Cunningham
Interim Chief Financial Officer
$433.94K––$433.94K+57%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jun 29, 2017
Offer price
$15.00
Securities offered
3,750,000
Gross proceeds
$56.25M
Exchange
Nasdaq
First trading day
Jun 29, 2017
First-day close
$10.80-28.0%
Lock-up ends (est.)
Dec 26, 2017

“The public offering price is $15.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 10 full-time employees, including a total of two employees with M.D.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?